

IN THE CLAIMS

Please cancel claims 4-6 and 70-72, amend claims 10, 79, 80, 81, 88 and 91-93 and add new claims 100-111.

This listing of claims will replace all prior version and listings of claims in the application.

Listing of Claims

1. (Previously presented) A method of treating an individual who has cancer that comprises cancer cells that have a high rate of aerobic glycolysis, the method comprising the steps of:
identifying said cancer as a cancer that comprises cancer cells that have a high rate of aerobic glycolysis, and subsequently
administering to said individual a therapeutically effective amount of an ATP citrate lyase inhibitor, wherein said therapeutically effective amount of ATP citrate lyase inhibitor is sufficient to inhibit ATP citrate lyase activity in said cancer cells to result in inhibition of conversion of citrate into oxaloacetic and acetyl-CoA in said cancer cells, leading to hyperpolarization of mitochondria and increased reactive oxygen species production sufficient to cause said cell to undergo apoptosis.
2. (Original) The method of claim 1 wherein said cancer is determined to be a cancer that comprises cancer cells that have a high rate of aerobic glycolysis by PET imaging.
3. (Original) The method of claim 1 wherein said cancer is determined to be a cancer that comprises cancer cells that have a high rate of aerobic glycolysis by PET imaging using ¹⁸fluoro-deoxyglucose.
- 4-7. (Canceled)
8. (Previously presented) The method of claim 1 comprising the step of administering to said individual a therapeutically effective amount of an ATP citrate lyase inhibitor; wherein said ATP

citrate lyase inhibitor is (-)hydroxycitrate.

9. (Withdrawn) The method of claim 1 comprising the step of administering to said individual a therapeutically effective amount of an ATP citrate lyase inhibitor; wherein said ATP citrate lyase inhibitor is SB-204990 shown in Figure 4.

10. (Currently amended) ~~A~~ The method of treating an individual identified as having cancer comprising cancer cells that have a high rate of aerobic glycolysis claim 1, wherein said cancer comprises cancer cells that have a high rate of aerobic glycolysis and are not dependent on endogenously synthesized fatty acid, said method comprising the steps of:

identifying said cancer as a cancer that comprises cancer cells that are not dependent on endogenously synthesized fatty acid and that have a high rate of aerobic glycolysis, and subsequently

administering to said individual a therapeutically effective amount of an ATP citrate lyase inhibitor, wherein said therapeutically effective amount of ATP citrate lyase inhibitor is sufficient to inhibit ATP citrate lyase activity in said cancer cells to result in inhibition of conversion of citrate into oxaloacetic and acetyl-CoA in said cancer cells, leading to hyperpolarization of mitochondria and increased reactive oxygen species production sufficient to cause said cell to undergo apoptosis.

11. (Canceled)

12. (Previously presented) The method of claim 10 wherein said cancer is determined to be a cancer with cancer cells that have a high rate of aerobic glycolysis by PET imaging.

13. (Original) The method of claim 12 wherein said cancer is determined to be a cancer with cancer cells that have a high rate of aerobic glycolysis by PET imaging using ¹⁸fluoro-deoxyglucose.

14. (Previously presented) The method of claim 10 wherein said ATP citrate lyase inhibitor is administered in conjunction with administration of a different anti-cancer compound.

15. (Previously presented) The method of claim 10 wherein said ATP citrate lyase inhibitor is administered in conjunction with administration of anti-cancer radiation therapy.

16. (Previously presented) The method of claim 10 further comprising administering to said individual a therapeutically effective amount of a tricarboxylate transporter inhibitor.

17-19. (Canceled)

20. (Previously presented) The method of claim 10 wherein ATP citrate lyase inhibitor is (-) hydroxycitrate.

21. (Withdrawn) The method of claim 10 wherein said ATP citrate lyase inhibitor is SB-204990 shown in Figure 4.

22-35. (Canceled)

36. (Previously presented) The method of claim 16 comprising the step of administering to said individual a therapeutically effective amount of a tricarboxylate transporter inhibitor, wherein said tricarboxylate transporter inhibitor is selected from the group consisting of: 1,2,3-benzenetricarboxylate, isocitrate, malate, phosphoenolpyruvate, n-butylmalonate, sulfhydryl reagents, diethyl pyrocarbonate, 2,3-butanedione, phenylglyoxal, pyridoxal, 5-phosphate dicarboxylates, succinate, malate, oxaloacetate, tricarboxylates isocitrate, tricarballylate and palmitoyl-CoA.

37-48. (Canceled)

49. (Previously presented) The method of claim 1 comprising the step of administering to said individual a therapeutically effective amount of a tricarboxylate transporter inhibitor; wherein said tricarboxylate transporter inhibitor is selected from the group consisting of: 1,2,3-benzenetricarboxylate, isocitrate, malate, phosphoenolpyruvate, n-butylmalonate, sulfhydryl reagents, diethyl pyrocarbonate, 2,3-butanedione, phenylglyoxal, pyridoxal, 5-phosphate dicarboxylates, succinate, malate, oxaloacetate, tricarboxylates isocitrate, tricarballylate and palmitoyl-CoA.

50. (Previously presented) The method of claim 1 comprising the step of further administering to said individual a different anti-cancer compound.

51. (Previously presented) The method of claim 1 comprising the step of further administering to said individual anti-cancer radiation therapy.

52-63. (Canceled)

64. (Previously presented) The method of claim 1 wherein said cancer is a glioma.

65. (Previously presented) The method of claim 10 wherein said cancer is a glioma.

66-67. (Canceled)

68. (Previously presented) The method of claim 1 wherein said cancer is selected from the

group consisting of glioma, prostate cancer, bladder cancer, renal cancer and lung cancer.

69. (Previously presented) The method of claim 10 wherein said cancer is selected from the group consisting of glioma, prostate cancer, bladder cancer, renal cancer and lung cancer.

70-74. (Canceled)

75. (Previously presented) The method of claim 1 further comprising the step of administering to said individual a therapeutically effective amount of a tricarboxylate transporter inhibitor.

76. (Previously presented) The method of claim 50 wherein different anti-cancer compound is an anti-cancer antibody.

77. (Previously presented) The method of claim 14 wherein different anti-cancer compound is an anti-cancer antibody.

78. (Canceled)

79. (Currently amended) ~~A~~ The method of treating an individual who has cancer that comprises cancer cells that have a high rate of aerobic glycolysis claim 1, wherein cancer cells having a high rate of aerobic glycolysis have activated Akt or deletion of PTEN, the method comprising the steps of:

identifying said cancer as a cancer that comprises cancer cells having a high rate of aerobic glycolysis that ~~are transformed by activation of~~ that have activated Akt or ~~by~~ deletion of PTEN, and subsequently

administering to said individual a therapeutically effective amount of an ATP citrate lyase inhibitor.

80. (Currently amended) The method of claim 79 wherein said cancer cells having a high rate of aerobic glycolysis ~~that are transformed by activation of~~ that have activated Akt,

81. (Currently amended) The method of claim 79 wherein said cancer cells having a high rate of aerobic glycolysis ~~that are transformed by~~ that have deletion of PTEN

82. (Previously presented) The method of claim 79 comprising the step of administering to said individual a therapeutically effective amount of an ATP citrate lyase inhibitor; wherein said ATP citrate lyase inhibitor is (-) hydroxycitrate.

83. (Previously presented) The method of claim 79 wherein said cancer is a glioma.

84. (Previously presented) The method of claim 79 wherein said cancer is selected from the group consisting of glioma, prostate cancer, bladder cancer, renal cancer and lung cancer.

85. (Previously presented) The method of claim 79 wherein said ATP citrate lyase inhibitor is administered in conjunction with administration of a different anti-cancer compound.

86. (Previously presented) The method of claim 85 wherein different anti-cancer compound is an anti-cancer antibody.

87. (Previously presented) The method of claim 79 wherein said ATP citrate lyase inhibitor is administered in conjunction with administration of anti-cancer radiation therapy.

88. (Currently amended) A method of treating an individual who has been identified as

having cancer that comprises cancer cells that have a high rate of aerobic glycolysis comprising the step of administering to said individual a therapeutically effective amount of an ATP citrate lyase inhibitor, wherein said therapeutically effective amount of ATP citrate lyase inhibitor is sufficient to inhibit ATP citrate lyase activity in said cancer cells to result in inhibition of conversion of citrate into oxaloacetic and acetyl-CoA in said cancer cells, leading to hyperpolarization of mitochondria and increased reactive oxygen species production sufficient to cause said cell to undergo apoptosis.

89. (Previously presented) The method of claim 88 wherein the individual was identified as having cancer that comprises cancer cells that have a high rate of aerobic glycolysis by PET imaging.

90. (Previously presented) The method of claim 88 wherein the individual was identified as having cancer that comprises cancer cells that have a high rate of aerobic glycolysis by PET imaging using ¹⁸fluoro-deoxyglucose.

91. (Currently amended) The method of claim 88 wherein the individual was identified as having cancer that comprises cancer cells having a high rate of aerobic glycolysis that have an activation of Akt or a deletion of PTEN.

92. (Currently amended) The method of claim 88 wherein the individual was identified as having cancer that comprises cancer cells having a high rate of aerobic glycolysis that have an activation of Akt.

93. (Currently amended) The method of claim 88 wherein the individual was identified as having cancer that comprises cancer cells having a high rate of aerobic glycolysis that have a deletion of PTEN

94. (Previously presented) The method of claim 88 comprising the step of administering to said individual a therapeutically effective amount of (-) hydroxycitrate.

95. (Previously presented) The method of claim 88 wherein said cancer is a glioma.

96. (Previously presented) The method of claim 88 wherein said cancer is selected from the group consisting of glioma, prostate cancer, bladder cancer, renal cancer and lung cancer.

97. (Previously presented) The method of claim 88 wherein said ATP citrate lyase inhibitor is administered in conjunction with administration of a different anti-cancer compound.

98. (Previously presented) The method of claim 97 wherein different anti-cancer compound is an anti-cancer antibody.

99. (Previously presented) The method of claim 88 wherein said ATP citrate lyase inhibitor is administered in conjunction with administration of anti-cancer radiation therapy.

100. (New) The method of claim 88 wherein the individual was identified as having cancer that comprises cancer cells that are not dependent on endogenously synthesized fatty acid and that have a high rate of aerobic glycolysis.

101. (New) The method of claim 89 wherein the individual was diagnosed as having cancer prior to PET imaging.

102. (New) The method of claim 101 wherein the PET imaging was done using ¹⁸fluoro-deoxyglucose.

103. (New) The method of claim 1 comprising the steps of:
diagnosing the individual as having cancer; subsequently
identifying said cancer as a cancer that comprises cancer cells that have a high rate of
aerobic glycolysis to PET imaging, and subsequently
administering to said individual the therapeutically effective amount of an ATP citrate
lyase inhibitor.
104. (New) The method of claim 103 wherein the PET imaging is done using ¹⁸fluoro-
deoxyglucose.
105. (New) The method of claim 103 wherein ATP citrate lyase inhibitor is (-) hydroxycitrate.
106. (New) The method of claim 103 wherein said cancer is a glioma.
107. (New) A method of treating an individual who has been identified as having cancer that
comprises cancer cells that have activated Akt or deletion of PTEN, the method comprising the
steps of:
identifying said cancer as a cancer that comprises cancer cells that have activated Akt or
deletion of PTEN, and subsequently
administering to said individual a therapeutically effective amount of an ATP citrate lyase
inhibitor.
108. (New) The method of claim 107, wherein said cancer comprises cancer cells that have
activated Akt or deletion of PTEN and are not dependent on endogenously synthesized fatty
acid, said method comprising the steps of:
identifying said cancer as a cancer that comprises cancer cells that are not dependent on
endogenously synthesized fatty acid and have activated Akt or deletion of PTEN, and

subsequently

administering to said individual a therapeutically effective amount of an ATP citrate lyase inhibitor.

109. (New) The method of claim 107 wherein said ATP citrate lyase inhibitor is administered in conjunction with an anti-cancer antibody.

110. (New) The method of claim 107 wherein ATP citrate lyase inhibitor is (-) hydroxycitrate.

111. (New) The method of claim 107 wherein said cancer is a glioma.